The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001254381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
27/09/2026
Date registered
Help: Date registered
14/10/2026
Date last updated
Help: Date last updated
14/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
14/10/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Effect of Enoxaparin Versus Aspirin On lower Limb venous Thrombo-Embolism Trial:
A prospective randomized controlled non-inferiority trial on adult patients with acute lower limb injuries
Scientific title
Effect of Enoxaparin Versus Aspirin On lower Limb venous Thrombo-Embolism Trial:
A prospective randomized controlled non-inferiority trial on adult patients with acute lower limb injuries
Additional trial identifiers [1] 304790 0
Nil known
Universal Trial Number (UTN)
Trial acronym
EVAPOLITE Trial
Related trial records

Health condition
Health condition(s) studied:
venous thromboembolism 343730 0
Condition category
Condition code
Emergency medicine 339845 339845 0 0
Other emergency care
Musculoskeletal 339846 339846 0 0
Other muscular and skeletal disorders
Blood 339847 339847 0 0
Clotting disorders
Injuries and Accidents 339848 339848 0 0
Fractures

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The eligible patients will be randomized to receive either one of the two the drugs according to the study sequence contained in the opaque sealed envelopes:

The Intervention group of patients will receive
Enoxaparin (®Clexane) 40mg (20 mg if CrCl < 30 ml/min, OR 0.5 mg/kg if >100kg) Subcutaneous injection once a day for 10 days

The participants or responsible caregivers will administer the subcutaneous injection of Enoxaparin at Emergency Department initially and then at home afterwards.
Intervention code [1] 335437 0
Prevention
Description of the comparator or control
The eligible patients will be randomized to receive either one of the two the drugs according to the study sequence contained in the opaque sealed envelopes:

The Control group of patients will receive
Aspirin 100 mg tablet Orally after or with meals once a day for 10 days,
Control group
Active

Outcomes
Primary outcome [1] 347024 0
Development of venous thromboembolism, e.g. Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) - composite. DVT will be confirmed or excluded on Doppler ultrasound of the affected lower limb of the participants. CT Pulmonary Angiogram will be used to investigate for pulmonary embolism in symptomatic patients who develop pleuritic chest pain, acute respiratory distress, hypoxia or unexplained syncope.
Timepoint [1] 347024 0
All participants will receive a lower limb vascular ultrasound at the time of Orthopaedic clinic review within the first 2 weeks after limb injury. They will be informed to return to have further imaging if becoming symptomatic later on.
Secondary outcome [1] 468601 0
development of side effects of enoxaparin and aspirin, e.g. increased cutaneous bruising / bleeding +/- muscle haematoma +/- joint haematoma +/- gum / nose bleeding +/- internal haemorrhage (haematemesis / melaena / Per Rectum bleeding / haemoptysis /.haematuria / menorrhagia / intracranial bleeding) - composite. Most of these bleeding side effects will be based on participants' observation and clinical examination findings. Internal bleeding such as intracranial haemorrhage will be assessed by the CT brain.
Timepoint [1] 468601 0
during the treatment period, i.e. within the first 2 weeks after limb injury in these participants

Eligibility
Key inclusion criteria
Consecutive adult patients (age at least 18 years) who will be discharged home from Emergency Department with plaster, CAM Boot, or Zimmer Knee splint.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Patients for admission from ED to wards directly

• Is already on anticoagulant (LMW heparin / Clexane, warfarin, novel oral anticoagulants)

• Contraindication to anticoagulant treatment

o Active haemorrhage

o Thrombocytopenia (Platelet < 50 x 109/L) or coagulopathy (INR >5)

o Intracranial haemorrhage within 1 year

o Craniotomy / spinal surgery / lumbar puncture within 2 weeks

o Intraocular surgery within 2 weeks

o Gastrointestinal / genitourinary surgery within 1 month

o postoperative bleeding concerns

o recent head injury within 3 days

o Hypertensive emergency (systolic BP > 180 mmHg, or diastolic BP > 110 mmHg)

• Heparin sensitivity or history of Heparin Induced Thrombocytopenia (HIT)

• Allergy to aspirin

• Meeting high risk criteria for venous thromboembolism (see below)



HIGH RISK CRITERIA

• Previous DVT / PE

• Known thrombophilia.

• Active cancer requiring ongoing treatment (i.e. not in remission or off cancer treatment for > 6 weeks)

• Sickle cell disease

• myeloproliferative neoplasm

• Obesity (BMI > 35 kg/m2)

• Lower limb paresis due to acute or previous injury, stroke, or wheelchair bound.

• Nephrotic syndrome

• Heart Failure NYHA Class III & IV

o Class I – Patients with heart disease without resulting limitation of physical activity. Ordinary physical activity does not cause heart failure symptoms such as fatigue or dyspnea. (Low Risk)

o Class II – Patients with heart disease resulting in slight limitation of physical activity. Symptoms of heart failure develop with ordinary activity but there are no symptoms at rest. (Low Risk)

o Class III – Patients with heart disease resulting in marked limitation of physical activity. Symptoms of heart failure develop with less than ordinary physical activity but there are no symptoms at rest. (High Risk)

o Class IV – Patients with heart disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure may occur even at rest. (High Risk)

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed opaque envelopes containing random drug sequence are used.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer-generated random sequence
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The sample size software PASS was utilised to determine that a pilot sample size of 48 participants in the control arm (so 96 patients in total when randomised 1:1 with the intervention arm) will allow for the main outcome to be estimated using an 80% confidence interval and a 10% margin of error, assuming a prevalence of 40%.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 30287 0
John Hunter Hospital - New Lambton
Recruitment hospital [2] 30288 0
The Maitland Hospital - Maitland
Recruitment postcode(s) [1] 46690 0
2305 - New Lambton
Recruitment postcode(s) [2] 46691 0
2320 - Maitland

Funding & Sponsors
Funding source category [1] 309164 0
Charities/Societies/Foundations
Name [1] 309164 0
ACEM Foundation Al Spilman Early Career Researcher Grant 2022
Country [1] 309164 0
Australia
Primary sponsor type
Hospital
Name
John Hunter Hospital
Address
Country
Australia
Secondary sponsor category [1] 326065 0
None
Name [1] 326065 0
Address [1] 326065 0
Country [1] 326065 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 309026 0
Hunter New England Human Research Ethics Committee
Ethics committee address [1] 309026 0
Ethics committee country [1] 309026 0
Australia
Date submitted for ethics approval [1] 309026 0
16/02/2023
Approval date [1] 309026 0
06/06/2023
Ethics approval number [1] 309026 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 112694 0
Dr Michael Zhang
Address 112694 0
Emergency Department, John Hunter Hospital, Lookout Road, New Lambton Heights, NSW 2305
Country 112694 0
Australia
Phone 112694 0
+61 249213000
Fax 112694 0
Email 112694 0
Contact person for public queries
Name 112695 0
Dr Michael Zhang
Address 112695 0
Emergency Department, John Hunter Hospital, Lookout Road, New Lambton Heights, NSW 2305
Country 112695 0
Australia
Phone 112695 0
+61 249213000
Fax 112695 0
Email 112695 0
Contact person for scientific queries
Name 112696 0
Michael Zhang
Address 112696 0
Emergency Department, John Hunter Hospital, Lookout Road, New Lambton Heights, NSW 2305
Country 112696 0
Australia
Phone 112696 0
+61 249213000
Fax 112696 0
Email 112696 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.